Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Attention Deficit Hyperactivity Disorder Market

Attention Deficit Hyperactivity Disorder Market Share

Report ID: GMI12095
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Attention Deficit Hyperactivity Disorder Market Share

The ADHD market is marked by a competitive landscape, fueled by growing diagnosis rates and demand for innovative treatments. Major pharmaceutical companies dominate, holding substantial market shares due to diverse ADHD medication portfolios and advanced therapeutic solutions. Strategic moves, including mergers, acquisitions, and partnerships, enhance the reach and market presence of leading players, enabling them to expand offerings across child and adult ADHD segments. With ongoing research and product development, these companies continue to capture new segments and respond to increasing demand for both stimulant and non-stimulant treatment options, broadening their influence in the ADHD treatment market globally.

Attention Deficit Hyperactivity Disorder Market Companies

Major players operating in the attention deficit hyperactivity disorder industry are:

Aytu BioPharma
Eli Lilly and Company
Ironshore
Janssen Pharmaceuticals
Lupin
Mallinckrodt
Novartis
Pfizer
Sun Pharmaceutical
Supernus Pharmaceutical
Takeda Pharmaceutical Company
Teva Pharmaceutical

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global attention deficit hyperactivity disorder industry was valued at USD 15.8 billion in 2023 and is estimated to grow at a 5.1% CAGR from 2024 to 2032, driven by the rising global prevalence of ADHD and advancements in diagnostic technologies.

The stimulants segment dominated the market with USD 11.2 billion in 2023, as these medications are highly effective, with approximately 70-80% of patients responding positively.

U.S. ADHD market is expected to grow at a 5.1% CAGR, reaching USD 10.2 billion by 2032, supported by high awareness and diagnosis rates, along with a strong focus on both medication and behavioral therapy sectors.

Key players in the industry include Aytu BioPharma, Eli Lilly and Company, Ironshore, Janssen Pharmaceuticals, Lupin, Mallinckrodt, Novartis, and Pfizer.